Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease

J Gastroenterol Hepatol. 1998 May;13(5):516-20. doi: 10.1111/j.1440-1746.1998.tb00679.x.

Abstract

C-X-C Chemokines play an important role for neutrophil extravasation through microvessels. Although the level of interleukin (IL)-8 is known to increase in the Helicobacter pylori-infected gastric mucosa, another C-X-C chemokine, GROalpha, has not been evaluated in the H. pylori-associated gastric mucosal injury. The present study was designed to investigate gastric contents of GROalpha in relation to those of IL-8 in the gastric mucosa of H. pylori-infected peptic ulcer patients. Thirty-eight patients with gastric ulcer and 41 with gastritis underwent endoscopy with informed consent and 49 were found to be H. pylori positive and 30 H. pylori negative. Biopsies from the gastric corpus were performed in each patient to examine the H. pylori colonization by bacterial culture, the rapid urease test and histological specimens as well as measurement of the contents of human GROalpha and IL-8. Helicobacter pylori infection was eradicated in 21 patients by triple therapy (lansoprazole 30 mg, amoxycillin 2.0 g, clarithromycin 600 mg; 2 weeks). The samples for GROalpha and IL-8 assay were homogenized in 0.02% aprotinin containing phosphate-buffered solution and the mucosal contents of GROalpha and IL-8 in the supernatants were quantified by sandwich enzyme immunoassay methods. The levels of GROalpha and IL-8 in H. pylori-positive gastric mucosa were significantly higher than those in the H. pylori-negative mucosa. There was a significant linear correlation between the levels of GROalpha and IL-8 (r = 0.798, P < 0.01). After the eradication of H. pylori by the triple therapy, the levels of GROalpha and IL-8 were significantly decreased. The GROalpha showed an increase in the H. pylori-positive gastric mucosa in a similar fashion as IL-8 contents, suggesting a pathogenetic role for GROalpha in H. pylori-associated gastric mucosal injury.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Adult
  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Ulcer Agents / therapeutic use
  • Chemokine CXCL1
  • Chemokines, CXC / metabolism
  • Chemotactic Factors / metabolism*
  • Gastric Mucosa / drug effects
  • Gastric Mucosa / metabolism*
  • Gastric Mucosa / microbiology
  • Gastritis / drug therapy
  • Gastritis / metabolism
  • Gastritis / microbiology
  • Growth Substances / metabolism*
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / metabolism*
  • Helicobacter pylori / isolation & purification*
  • Humans
  • Intercellular Signaling Peptides and Proteins*
  • Interleukin-8 / metabolism
  • Lansoprazole
  • Middle Aged
  • Omeprazole / analogs & derivatives
  • Omeprazole / therapeutic use
  • Stomach Diseases / drug therapy
  • Stomach Diseases / metabolism*
  • Stomach Diseases / microbiology
  • Stomach Ulcer / drug therapy
  • Stomach Ulcer / metabolism
  • Stomach Ulcer / microbiology

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Anti-Bacterial Agents
  • Anti-Ulcer Agents
  • CXCL1 protein, human
  • Chemokine CXCL1
  • Chemokines, CXC
  • Chemotactic Factors
  • Growth Substances
  • Intercellular Signaling Peptides and Proteins
  • Interleukin-8
  • Lansoprazole
  • Omeprazole